On January 31st, Novo Nordisk released its 2023 results, with annual revenue of approximately $33.771 billion, a year-on-year increase of 31%. As a star product of Novo Nordisk, Smegglutide earned approximately $21.201 billion in sales in 2023.
Driven by GLP-1 drugs such as Smegglutide, Novo Nordisk's performance growth has continued to be strong, once again verifying the logic of the pharmaceutical's large single product. AVIC Securities believes that the concept of weight loss is still a track of rapid growth in demand, and the advantages of domestic raw materials and CDMO industry chains will be fully utilized.
Related ETFs: Hang Seng Pharmaceutical ETF (159892), holding CXO leading companies such as WuXi Biotech, WuXi AppTec, and Kanglong Huacheng